When is an Automated Implantable Cardioverter-Defibrillator (AICD) with pacemaker recommended over an AICD only?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Use AICD with Pacemaker vs. AICD Only

An AICD with pacemaker functionality (dual-chamber device) is recommended over an AICD-only device when patients have an indication for bradycardia pacing, require antitachycardia pacing for VT termination, or need cardiac resynchronization therapy. 1

Indications for AICD with Pacemaker

Definite Indications (Class I)

  • Symptomatic sinus node dysfunction requiring atrial pacing 1
  • Documented second- or third-degree AV block requiring pacing 1
  • Sustained pause-dependent ventricular tachycardia, with or without QT prolongation 1
  • Bradycardia limiting the use of necessary beta-blockers or other negative chronotropic medications 1

Reasonable Indications (Class IIa)

  • Bradycardia-induced or pause-dependent ventricular tachyarrhythmias (such as in long QT syndrome with torsades de pointes) 1
  • High-risk patients with congenital long-QT syndrome who require both defibrillation and pacing capabilities 1

Possible Indications (Class IIb)

  • Documented history of atrial arrhythmias (but not permanent atrial fibrillation) where atrial pacing may be beneficial 1
  • Hypertrophic cardiomyopathy with significant resting or provocable left ventricular outflow tract gradient where AV synchrony is important 1

When AICD-Only is Appropriate

  • No indication for bradycardia pacing and no anticipated need for pacing in the future 1
  • Permanent or longstanding persistent atrial fibrillation with no plans to restore sinus rhythm 1
  • Conditions likely to result in VF rather than monomorphic/polymorphic VT without bradycardia-induced mechanisms (e.g., idiopathic ventricular fibrillation, Brugada syndrome, catecholaminergic polymorphic VT, short QT syndrome) 1

Clinical Evidence and Considerations

  • In the MADIT-II trial, approximately 5.2% of patients with post-MI reduced ejection fraction required pacemaker or CRT implantation during a median follow-up of 20 months, with symptomatic sinus bradycardia being the most common indication (37%) 2

  • Risk factors for subsequent pacemaker need include:

    • PR interval >200 ms (HR = 3.07)
    • Prior CABG (HR = 6.88) 2
  • The DAVID trial demonstrated that unnecessary dual-chamber pacing (DDDR-70) in patients without pacing indications was associated with worse outcomes compared to minimal ventricular backup pacing (VVI-40), highlighting the importance of appropriate device selection 3

Subcutaneous ICD Considerations

  • Subcutaneous ICDs should NOT be implanted in patients with:

    • Indications for bradycardia pacing
    • Need for cardiac resynchronization therapy
    • Requirement for antitachycardia pacing for VT termination 1
  • Subcutaneous ICDs are recommended (Class I) for patients who:

    • Meet criteria for an ICD
    • Have inadequate vascular access or high infection risk
    • Have no need for pacing functions 1

Practical Algorithm for Decision-Making

  1. Assess for pacing indications:

    • Evaluate for symptomatic bradycardia, conduction disorders, or pause-dependent arrhythmias 1
    • Review ECG for PR prolongation (>200 ms) or other conduction abnormalities 2
  2. Consider cardiac condition:

    • Patients with certain conditions (long QT syndrome, hypertrophic cardiomyopathy) may benefit from dual-chamber devices 1
    • Assess for atrial arrhythmias that might benefit from atrial pacing 1
  3. Evaluate future pacing needs:

    • Consider risk factors for developing bradycardia (medications, comorbidities) 1
    • Weigh the morbidity of potential future upgrade procedures against initial dual-chamber implantation 1

Common Pitfalls to Avoid

  • Unnecessary dual-chamber device implantation in patients without pacing indications can lead to increased complications and potentially worse outcomes 3

  • Failure to recognize existing or potential bradycardia requiring pacing support, particularly in patients on beta-blockers or other negative chronotropic agents 1

  • Implanting a subcutaneous ICD in patients who may develop a need for pacing, necessitating a future system replacement 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.